OBJECTIVE: To evaluate the isoflurane-sparing effects of an intravenous (IV) constant rate infusion (CRI) of fentanyl, lidocaine, ketamine, dexmedetomidine, or lidocaine-ketamine-dexmedetomidine (LKD) in dogs undergoing ovariohysterectomy. STUDY DESIGN: Randomized, prospective, blinded, clinical study. ANIMALS: Fifty four dogs. METHODS: Anesthesia was induced with propofol and maintained with isoflurane with one of the following IV treatments: butorphanol/saline (butorphanol 0.4 mg kg(-1), saline 0.9% CRI, CONTROL/BUT); fentanyl (5 μg kg(-1), 10 μg kg(-1) hour(-1), FENT); ketamine (1 mg kg(-1), 40 μg kg(-1) minute(-1), KET), lidocaine (2 mg kg(-1), 100 μg kg(-1) minute(-1), LIDO); dexmedetomidine (1 μg kg(-1), 3 μg kg(-1) hour(-1), DEX); or a LKD combination. Positive pressure ventilation maintained eucapnia. An anesthetist unaware of treatment and end-tidal isoflurane concentration (Fe'Iso) adjusted vaporizer settings to maintain surgical anesthetic depth. Cardiopulmonary variables and Fe'Iso concentrations were monitored. Data were analyzed using anova (p < 0.05). RESULTS: At most time points, heart rate (HR) was lower in FENT than in other groups, except for DEX and LKD. Mean arterial blood pressure (MAP) was lower in FENT and CONTROL/BUT than in DEX. Overall mean ± SD Fe'Iso and % reduced isoflurane requirements were 1.01 ± 0.31/41.6% (range, 0.75 ± 0.31/56.6% to 1.12 ± 0.80/35.3%, FENT), 1.37 ± 0.19/20.8% (1.23 ± 0.14/28.9% to 1.51 ± 0.22/12.7%, KET), 1.34 ± 0.19/22.5% (1.24 ± 0.19/28.3% to 1.44 ± 0.21/16.8%, LIDO), 1.30 ± 0.28/24.8% (1.16 ± 0.18/32.9% to 1.43 ± 0.32/17.3%, DEX), 0.95 ± 0.19/54.9% (0.7 ± 0.16/59.5% to 1.12 ± 0.16/35.3%, LKD) and 1.73 ± 0.18/0.0% (1.64 ± 0.21 to 1.82 ± 0.14, CONTROL/BUT) during surgery. FENT and LKD significantly reduced Fe'Iso. CONCLUSIONS AND CLINICAL RELEVANCE: At the doses administered, FENT and LKD had greater isoflurane-sparing effect than LIDO, KET or CONTROL/BUT, but not at all times. Low HR during FENT may limit improvement in MAP expected with reduced Fe'Iso.
OBJECTIVE: To evaluate the isoflurane-sparing effects of an intravenous (IV) constant rate infusion (CRI) of fentanyl, lidocaine, ketamine, dexmedetomidine, or lidocaine-ketamine-dexmedetomidine (LKD) in dogs undergoing ovariohysterectomy. STUDY DESIGN: Randomized, prospective, blinded, clinical study. ANIMALS: Fifty four dogs. METHODS: Anesthesia was induced with propofol and maintained with isoflurane with one of the following IV treatments: butorphanol/saline (butorphanol 0.4 mg kg(-1), saline 0.9% CRI, CONTROL/BUT); fentanyl (5 μg kg(-1), 10 μg kg(-1) hour(-1), FENT); ketamine (1 mg kg(-1), 40 μg kg(-1) minute(-1), KET), lidocaine (2 mg kg(-1), 100 μg kg(-1) minute(-1), LIDO); dexmedetomidine (1 μg kg(-1), 3 μg kg(-1) hour(-1), DEX); or a LKD combination. Positive pressure ventilation maintained eucapnia. An anesthetist unaware of treatment and end-tidal isoflurane concentration (Fe'Iso) adjusted vaporizer settings to maintain surgical anesthetic depth. Cardiopulmonary variables and Fe'Iso concentrations were monitored. Data were analyzed using anova (p < 0.05). RESULTS: At most time points, heart rate (HR) was lower in FENT than in other groups, except for DEX and LKD. Mean arterial blood pressure (MAP) was lower in FENT and CONTROL/BUT than in DEX. Overall mean ± SD Fe'Iso and % reduced isoflurane requirements were 1.01 ± 0.31/41.6% (range, 0.75 ± 0.31/56.6% to 1.12 ± 0.80/35.3%, FENT), 1.37 ± 0.19/20.8% (1.23 ± 0.14/28.9% to 1.51 ± 0.22/12.7%, KET), 1.34 ± 0.19/22.5% (1.24 ± 0.19/28.3% to 1.44 ± 0.21/16.8%, LIDO), 1.30 ± 0.28/24.8% (1.16 ± 0.18/32.9% to 1.43 ± 0.32/17.3%, DEX), 0.95 ± 0.19/54.9% (0.7 ± 0.16/59.5% to 1.12 ± 0.16/35.3%, LKD) and 1.73 ± 0.18/0.0% (1.64 ± 0.21 to 1.82 ± 0.14, CONTROL/BUT) during surgery. FENT and LKD significantly reduced Fe'Iso. CONCLUSIONS AND CLINICAL RELEVANCE: At the doses administered, FENT and LKD had greater isoflurane-sparing effect than LIDO, KET or CONTROL/BUT, but not at all times. Low HR during FENT may limit improvement in MAP expected with reduced Fe'Iso.
Authors: Rafael Moran-Muñoz; Alexander Valverde; J A Ibancovichi; Carlos M Acevedo-Arcique; Sergio Recillas-Morales; Pedro Sanchez-Aparicio; Jorge Osorio-Avalos; Julio Raul Chavez-Monteagudo Journal: Can Vet J Date: 2017-07 Impact factor: 1.008
Authors: Emily M David; Cholawat Pacharinsak; Katechan Jampachaisri; Lisa Hagan; James O Marx Journal: J Am Assoc Lab Anim Sci Date: 2022-08-08 Impact factor: 1.706
Authors: Carlos M Acevedo-Arcique; José A Ibancovichi; Julio R Chavez; Eduardo Gutierrez-Blanco; Rafael Moran-Muñoz; José M Victoria-Mora; Francisco Tendillo-Cortijo; Martín Santos-González; Pedro Sanchez-Aparicio Journal: PLoS One Date: 2014-09-18 Impact factor: 3.240
Authors: Rafael Moran-Muñoz; J A Ibancovichi; Eduardo Gutierrez-Blanco; Carlos M Acevedo-Arcique; J Mauro Victoria Mora; Francisco J Tendillo; Martin Santos-Gonzalez; Kazuto Yamashita Journal: J Vet Med Sci Date: 2014-02-27 Impact factor: 1.267
Authors: Julio R Chavez; José A Ibancovichi; Pedro Sanchez-Aparicio; Carlos M Acevedo-Arcique; Rafael Moran-Muñoz; Sergio Recillas-Morales Journal: PLoS One Date: 2015-11-25 Impact factor: 3.240